Tumor biopsy is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Gustave Roussy, Cancer Campus, Grand Paris, with a possible patent signal linked through modality_match. Manual review is still required.
Target: Unknown
Cell type: Unknown
Indications: Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Institution: Gustave Roussy, Cancer Campus, Grand Paris
Phase: Na
Status: Recruiting
Trial count: 1
Active trials: 0
First posted: August 1, 2022
Last updated: June 24, 2025
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT05481502